血管内微轴左心室辅助装置的使用作为心脏性休克的桥梁策略:中期结果
Balakrishnan Mahesh1, Prasanth Peddaayyavarla2, Kenny Nguyen3
1Heart and Vascular Institute, Pennsylvania State Milton S Hershey Medical Center, Hershey, PA 17033, USA.
Journal of clinical medicine
|November 27, 2024
概括
血管内微轴左心室辅助器件 (M-LVADs) 显示,心脏性休克需要桥梁移植或耐用LVADs的患者的生存率很好. M-LVAD还为心脏切除术后的康复提供了合理的生存期,减少了ECMO的使用.
科学领域:
- 心脏病学 心脏病学
- 医疗器械 医疗器械
- 关键护理医学 关键护理医学
背景情况:
- 心脏性休克 (CS) 在心血管保健中提出了关键的挑战.
- 血管内微轴左心室辅助器件 (M-LVADs) 为CS患者提供了一个潜在的治疗选择.
- M-LVAD可以作为恢复或最终治疗的桥梁.
研究的目的:
- 为了评估M-LVAD植入心脏病性休克患者的中期结果.
- 确定使用M-LVADs治疗的CS患者早期和晚期死亡的预测因素.
- 为了比较M-LVAD使用的不同适应症的生存率.
主要方法:
- 对从2020年1月到2024年5月植入M-LVAD的107名CS患者进行了回顾性分析.
- 根据预期的治疗方法,患者被分为几组:桥梁到移植,桥梁到持久的LVAD和心脏切开后的CS (PCCS).
- 多变量后勤和考克斯回归模型被用于确定死亡率预测因素,统计显著性设置为p < 0.05.
主要成果:
- 并发症包括设备故障 (6%),胃肠道出血 (9%),长期透析 (21%),下血瘤 (10%),HIT (4%) 和中风 (11%).
- 早期医院死亡率为12% (13/107),在PCCS组显著更高 (p=0.02).
- 在4.5年时,精算生存率为90.7% (移植),79.2% (持久性LVAD) 和62.8% (PCCS) (p=0.01),M-LVAD类别和长期透析预测死亡率.
结论:
- 在CS患者中,M-LVAD表现出有利的中期存活率,作为移植或持久LVAD桥梁.
- 在心脏切割术后恢复的M-LVAD可以实现合理的生存,这与减少ECMO使用和早期康复有关.
- 在这个群体中,M-LVAD类别和长期透析的需要是死亡率的重要预测因素.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Mitral Regurgitation III: Medical Management
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...


